Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
2
33%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

completed350%
terminated350%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
terminatedphase_3

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03711162
terminatedphase_2

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648
completedphase_2

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366
completedphase_1

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

NCT03515382
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03733444Phase 3

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Terminated
NCT03711162Phase 3

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Terminated
NCT03976648Phase 2

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Terminated
NCT03798366Phase 2

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

Completed
NCT03515382Phase 1

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Completed
NCT03143712Phase 1

Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6